Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
50 Results for "
TDO
" in MedChemExpress (MCE) Product Catalog:
Products (50)
50 Results for "TDO" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease .
1
1 Cited Publications
Cat. No.: HY-33298
CAS No.: 1316695-35-8
Research Areas:
LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases .
1
1 Cited Publications
Research Areas:
IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders .
1
1 Cited Publications
Synonyms: IDO/TDO Inhibitor
Research Areas:
IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
Cat. No.: HY-177086
CAS No.: 1878200-88-4
Research Areas:
IDO1/TDO-IN-9 (Compound 66) is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) with IC50s of <1 μM. IDO1/TDO-IN-9 inhibits the activity of IDO1 and TDO, blocking tryptophan degradation to kynurenine, restoring immune activity in the tumor microenvironment, and suppressing tumor growth. IDO1/TDO-IN-9 is promising for research of cancers .
Research Areas:
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .
Research Areas:
IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
Cat. No.: HY-112867
CAS No.: 496023-55-3
Research Areas:
Amg-1 is a potent, reversible and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor (IC50 = 3.0 μM). Amg-1 exhibits >80-fold selectivity over IDO2 (IC50 > 250 μM) and >20-fold selective over TDO (IC50 > 62.5 μM). Amg-1 can be used for cancer, hypotension, and neurological disorders research .
Cat. No.: HY-W113615
CAS No.: 1680-44-0
Research Areas:
4-Phenyl-1H-1,2,3-triazole is a selective IDO1 inhibitor with an IC50 of 83 μM against human IDO1. 4-Phenyl-1H-1,2,3-triazole binds to the heme iron of IDO1 and occupies its active site, thereby inhibiting tryptophan catabolism. 4-Phenyl-1H-1,2,3-triazole can serve as a precursor for the synthesis of HIV-1 capsid protein inhibitors. 4-Phenyl-1H-1,2,3-triazole is applicable to research related to cancer and organic synthesis .
Cat. No.: HY-170322
Research Areas:
TDO2-IN-1 is a selective TDO2 inhibitor. TDO2-IN-1 binds to the active pocket, heme-binding pocket and substrate-binding pocket of apo-TDO2, interacts with key residues, competitively inhibits heme insertion, and suppresses intracellular TDO2 activity. TDO2-IN-1 can be used in research related to cancer, metabolism and other fields .
Cat. No.: HY-178470
Research Areas:
IDO1/TDO-IN-10 (Compound G-14) is a dual IDO1 (EC50=3.07 μM) and TDO (EC50=9.7 μM) inhibitor. IDO1/TDO-IN-10 inhibits the conversion of tryptophan to kynurenine and modulates immune responses while reducing inflammatory reactions. IDO1/TDO-IN-10 is promising for research of cancers and inflammatory diseases .
Cat. No.: HY-W103225
CAS No.: 613-31-0
Dihydroanthracene (9,10-Dihydroanthracene) is a substrate for toluene dioxygenase (TDO) expressed by Pseudomonas putida UV4. Toluene dioxygenase (TDO) expressed by Pseudomonas putida UV4 catalyzes the benzylic monooxygenation of Dihydroanthracene to 9-hydroxy-9,10-DHA as the only product .
Cat. No.: HY-114319
CAS No.: 57605-81-9
Target:
Research Areas:
IDO1/TDO-IN-2 (Compound 1) is a potent inhibitor of IDO1/TDO with IC50s of 0.1 and 0.07 μM. IDO1/TDO-IN-2 has the potential for the research of cancer diseases .
Cat. No.: HY-146674
CAS No.: 2347579-03-5
Research Areas:
IDO1/TDO-IN-3 is a potent inhibitor of IDO1/TDO. IDO1/TDO-IN-3 exhibits significant activities against IDO1 (IC50: 0.005 μM) and TDO (IC50: 0.004 μM). IDO1/TDO-IN-3 shows considerable in vivo anti-tumor activity and no obvious toxicity is observed .
Cat. No.: HY-144778
CAS No.: 2379527-72-5
Research Areas:
IDO1/TDO-IN-1 (30) is a potent dual IDO1 (uncompetitive, Ki of 0.23 μM) and TDO (competitive, Ki of 0.73 μM) inhibitor. IDO1/TDO-IN-1 (30) significantly promotes cell apoptosis through the potential mitochondria-mediated Bcl-2/Bax pathway .
Cat. No.: HY-162962
Research Areas:
IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model .
Cat. No.: HY-RS14331
Target:
Research Areas:
TDO2 Human Pre-designed siRNA Set A contains three designed siRNAs for TDO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-134920
CAS No.: 2116519-76-5
Research Areas:
LW106 is a selective IDO1 inhibitor with an IC50 of 1.57 μM. LW106 has no inhibitory effect on IDO2 and TDO. LW106 inhibits tumor outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumor microenvironment. LW106 reduces subpopulation of cancer stem cells (CSCs) in xenografted tumors in which less proliferative/invasive tumor cells and more tumor cells apoptosis. LW106 can be used for the studies of lung cancer and melanoma .
Cat. No.: HY-172874
Research Areas:
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
